Supernus Pharmaceuticals, Inc.
DE ˙ DB ˙ US8684591089
37,80 € 0,00 (0,00%)
2026-06-04
DEL PRIS
SecurityDE:S49 / Supernus Pharmaceuticals, Inc.
InstitutionQuantinno Capital Management LP
Latest Disclosed Ownership26,209 shares
Latest Disclosed Value $ 1,354,743
Quantinno Capital Management LP reports 7.45% increase in ownership of S49 / Supernus Pharmaceuticals, Inc.

On May 15, 2026 - Quantinno Capital Management LP filed a 13F-HR form disclosing ownership of 26,209 shares of Supernus Pharmaceuticals, Inc. (DE:S49) valued at $1,132,229 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 24,391 shares of Supernus Pharmaceuticals, Inc.. This represents a change in shares of 7.45% during the quarter. The current value of the position is $990,700 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 26,209 1,818 7.45 1,355 11.72 0.0023
2026-02-17 2025-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 24,391 3,525 16.89 1,212 21.56 0.0024
2025-11-14 2025-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 20,866 6,193 42.21 997 115.80 0.0027
2025-08-14 2025-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 14,673 4,302 41.48 462 36.28 0.0020
2025-05-12 2025-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 10,371 1,970 23.45 340 11.88 0.0022
2025-02-14 2024-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 8,401 864 11.46 304 28.94 0.0030
2024-11-14 2024-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 7,537 -68 -0.89 235 15.76 0.0031
2024-08-14 2024-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 7,605 835 12.33 203 -12.12 0.0037
2024-05-14 2024-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 6,770 6,770 231 0.0050
2023-08-04 2023-06-30 13F SUPERNUS PHARMACEUTICALS COM 4.000% 1/1 2/0 0.625% 4/0 868459108 0 -6,305 -100.00 0 -100.00
2023-05-03 2023-03-31 13F SUPERNUS PHARMACEUTICALS COM 4.000% 1/1 2/0 0.625% 4/0 868459108 6,305 0 0.00 228 1.33 0.0151
2023-02-13 2022-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 6,305 -14 -0.22 225 5.14 0.0168
2022-11-08 2022-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 6,319 6,319 214 0.0276
2022-02-14 2021-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 0 -10,188 -100.00 0 -100.00
2021-11-15 2021-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 10,188 0 0.00 272 -13.38 0.3036
2021-08-16 2021-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 10,188 0 0.00 314 17.60 0.3560
2021-05-17 2021-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 10,188 -10,119 -49.83 267 -47.75 0.2910
2021-02-09 2020-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 20,307 -6,732 -24.90 511 -9.24 0.3950
2020-11-16 2020-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 27,039 27,039 563 0.3765
2020-08-14 2020-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 0 -35,663 -100.00 0 -100.00
2020-05-15 2020-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 35,663 35,663 642 0.4009
2020-02-14 2019-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 0 -14,482 -100.00 0 -100.00
2019-11-14 2019-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 14,482 14,482 398 0.2680
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.